Global Narcolepsy Market to 2027: A $4.53 Billion Opportunity – ResearchAndMarkets.com

Market to 2027 – Global Analysis and Forecasts by Type; Distribution
Channel and Geography”
report has been added to ResearchAndMarkets.com’s

The global narcolepsy market is expected to reach US$ 4,537.9 Mn in 2027
from US$ 2,026.8 Mn in 2018. The market is estimated to grow with a CAGR
of 9.5% from 2019-2027.

The growth of the narcolepsy market is primarily attributed to the
rising prevalence of sleep related neurological disorders, emerging
local pharmaceutical and biopharmaceutical companies, and increasing
awareness regarding neurological disorders. However, side effects and
risks associated with the narcolepsy medications and delayed diagnosis
and misdiagnosis of the disease are likely to pose a negative impact on
the market growth.

On the other hand, robust pipeline of drugs intended for the treatment
of narcolepsy is likely to have a positive impact on the growth of the
global narcolepsy market in the coming years. The range of sleep
disorders that are treated by neurologists is wide and includes
conditions such as insomnia, sleep apnea, restless legs syndrome, and
narcolepsy. These disorders cause disruptions in the normal sleep-wake
mechanisms causing endogenous abnormalities. Neurological sleep related
disorders are an emerging problem as the population is aging at a rapid

According to the National Institute of Health (NIH), approximately 40
million Americans suffer from neurological diseases in the US, whereas
additional 20 million people experience occasional sleeping problems.
Sleep attacks are not limited to periods of dull or low engagement
activities, but can happen during school or work hours, in the middle of
a conversation, while eating, while exercising or playing sports, or
even while driving. The increasing prevalence of neurological sleep
disorders and narcolepsy is likely to foster the growth of market in the
coming years.

In 2018, the narcolepsy with cataplexy segment held a largest market
share of 65.1% of the narcolepsy market, by type. This segment is also
expected to dominate the market in 2027 owing to its significant
prevalence among patients suffering with narcolepsy. Episodes of
cataplexy are reported to be encountered among 55-60% of patients
suffering with narcolepsy. Moreover, the similar segment is anticipated
to also witness the fastest growth rate of 9.7% during the forecast
period, 2019 to 2027 owing to the increasing demand for drugs to treat
the disease.

Global narcolepsy market based on product was segmented into sodium
oxybate, CNS stimulants and antidepressants. Sodium oxybate segment is
anticipated to grow at a CAGR of 9.8% during the forecast period. Sodium
oxybate is the one of the primary medication recommended by specialists
to patients suffering with narcolepsy. The high cost of the branded
counterparts, availability of reimbursement with certain regions as well
as approval of the drug in majority of the top markets is likely to
contribute to the growth and dominance of the segment. Sodium is oxybate
is also expected to exhibit highest growth witnessing a robust CAGR over
the forecast years.

Some of the major primary and secondary sources for narcolepsy included
in the report are World Health Organization (WHO), European Medical
Agency (EMA), National Health Commission (NHC), China National Drug
Administration (CNDA), Food & Drug Administration (FDA), National
Institute of Neurological Disorders and Strokes, International
Federation of Pharmaceutical Manufacturers & Associations and others.

Topics Covered

1. Introduction

1.1 Scope of the Study

1.2 Report Guidance

1.3 Market Segmentation

1.3.1 Global Narcolepsy Market – by Type

1.3.2 Global Narcolepsy Market – by Product

1.3.3 Global Narcolepsy Market – by Distribution Channel

1.3.4 Global Narcolepsy Market – by Geography

2. Global Narcolepsy Market – Key Takeaways

3. Research Methodology

3.1.1 Coverage

3.1.2 Secondary Research

3.1.3 Primary Research

4. Global Narcolepsy Market – Market Landscape

4.1 Overview

4.2 Pest Analysis

4.2.1 North America – Pest Analysis

4.2.2 Europe- Pest Analysis

4.2.3 Asia Pacific- Pest Analysis

4.2.4 Middle East & Africa- Pest Analysis

4.2.5 South and Central America – Pest Analysis

5. Global Narcolepsy Market – Key Market Dynamics

5.1 Key Market Drivers

5.1.1 Rising Prevalence of Sleep Related Neurological Disorders

5.1.2 Emerging Local Pharmaceutical and Biopharmaceutical Companies

5.1.3 Increasing Awareness Regarding Neurological Disorders

5.2 Key Market Restraints

5.2.1 Side Effects and Risks Associated With Narcolepsy Medications

5.2.2 Delayed Diagnosis Or Misdiagnosis of Narcolepsy

5.3 Key Market Opportunities

5.3.1 Robust Pipeline Drugs For Narcolepsy

5.4 Future Trends

5.4.1 New Treatments For Narcolepsy

5.5 Impact Analysis

6. Narcolepsy Market – Global Analysis

6.1 Global Narcolepsy Market Revenue Forecasts and Analysis

6.2 Global Narcolepsy Market, by Geography – Forecasts and Analysis

6.3 Performance of Key Players

6.3.1 Jazz Pharmaceuticals Plc

6.3.2 Teva Pharmaceutical Industries Ltd.

6.4 Brand Analaysis

6.4.1 Marketed Drugs:

6.4.2 Provigil Overview: Drug Description: Advantages & Disadvantages:

6.4.3 Xyrem Overview: Drug Description: Advantages & Disadvantages:

6.4.4 Nuvigil Overview: Drug Description: Advantages & Disadvantages:

6.5 Pipeline Analysis

7. Narcolepsy Market Analysis and Forecasts To 2027 – Type

7.1 Overview

7.2 Type Market Revenue and Forecasts Analysis (US$ Mn)

7.3 Narcolepsy With Cataplexy Market

7.3.1 Overview

7.3.2 Narcolepsy With Cataplexy Market Revenue and Forecast To 2027 (US$

7.4 Narcolepsy Without Cataplexy Market

7.4.1 Overview

7.4.2 Narcolepsy Without Cataplexy Market Revenue and Forecast To 2027
(US$ Mn)

7.5 Secondary Narcolepsy Market

7.5.1 Overview

7.5.2 Secondary Narcolepsy Market Revenue and Forecast To 2027 (US$ Mn)

8. Narcolepsy Market Analysis and Forecasts To 2027 – Product

8.1 Overview

8.2 Product Market Revenue and Forecasts Analysis (US$ Mn)

8.3 Central Nervous System Stimulants Market

8.3.1 Overview

8.3.2 Central Nervous System Stimulants Market Revenue and Forecast To
2027 (US$ Mn)

8.4 Sodium Oxybate Market

8.4.1 Overview

8.4.2 Sodium Oxybate Market Revenue and Forecast To 2027 (US$ Mn)

8.5 Antidepressants Market

8.5.1 Overview

8.5.2 Antidepressants Market Revenue and Forecast To 2027 (US$ Mn)

9. Narcolepsy Market Analysis and Forecasts To 2027 – Distribution

9.1 Overview

9.2 Distribution Channel Market Revenue and Forecasts Analysis (US$ Mn)

9.3 Hospital Pharmacies Market

9.3.1 Overview

9.3.2 Hospital Pharmacies Market Revenue and Forecast To 2027 (US$ Mn)

9.4 Retail Pharmacies Market

9.4.1 Overview

9.4.2 Retail Pharmacies Market Revenue and Forecast To 2027 (US$ Mn)

10. Narcolepsy Market Revenue and Forecasts To 2027 – Geographical

10.1 North America Narcolepsy Market

10.2 Europe Narcolepsy Market

10.3 Asia Pacific Narcolepsy Market

10.4 Middle East & Africa Narcolepsy Market

10.5 South and Central America Narcolepsy Market

11. Narcolepsy Market – Industry Landscape

11.1 Overview

11.2 Comparative Company Analysis

11.3 Growth Strategies In the Narcolepsy Market, 2015-2018

11.4 Organic Growth Strategies

11.4.1 Overview

11.4.2 Expansions

11.4.3 Product Launches

11.4.4 Other Organic Growth Strategies

11.5 Inorganic Growth Strategies

11.5.1 Overview

11.5.2 Agreements

11.5.3 Acquisitions

11.5.4 Other Inorganic Growth Strategies

12. Narcolepsy Market -Key Company Profiles

12.1 Teva Pharmaceutical Industries Ltd.

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Financial Overview

12.1.4 Product Portfolio

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Jazz Pharmaceuticals Plc

12.3 Arena Pharmaceuticals, Inc.

12.4 Graymark Healthcare, Inc.

12.5 Novartis Ag

12.6 Takeda Pharmaceutical Company Limited

12.7 Mylan N.V.

12.8 Bioprojet

12.9 Shionogi & Co., Ltd.

12.10 Ligand Pharmaceuticals, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/8nlq3v/global_narcolepsy?w=4


Laura Wood, Senior Press Manager
[email protected]
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Central
Nervous System Drugs

Read the full article